{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Diagram of Hierarchical Testing of Primary and Secondary Endpoints is described in', 'Figure 3.', 'Figure 3.', 'Diagram of Hierarchical Testing of Primary and Secondary', 'Enppoints', 'Test Hola (PFS in DLL3 High set) at one-sided a = 0.25%', 'If Hola not rejected', 'If Holai is rejected', 'Test Holb (OS in DLL High', 'Test Holb (OS in DLL3High', 'set) at one-sided a = 2.2499%', 'set) at one-sided a = 2.4999%', 'If Holb isrejected', 'If Holb is rejected', 'Test Ho2 (OS in Randomized', 'Test Ho2 (OS in Randomized', 'set) at one-sided a = 2.2499%', 'set) at one-sided a = 2.4999%', 'If Ho2 is rejected', 'If H02 is rejected', 'Test Ho4 (PF scale in EORTC', 'Test H03 (PFS in Randomized', 'QLQ-C30 in Randomized set)', 'set) at one-sided a = 2.4999%', 'at one-sided a = 2.2499%', 'If Ho3 is rejected', 'Test Ho4 (PF scale in EORTC', 'QLQ-C30 in Randomized set)', 'at one-sided a = 2.2499%', '196']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Section 8.4 Determination of Sample Size', 'Previously read:', 'There are two primary efficacy endpoints for this study: Progression-free survival (PFS)', 'based on the CRAC and overall survival (OS). To maintain the overall 1-sided type I', 'error at a 2.5% for this study, the type I error will be split, assigning 0.25% to', 'progression-free survival and the remaining 2.25% to overall survival.', 'The sample size of the study is primarily determined by the analysis of OS. It is assumed,', 'taking into account the expected patient population for the study, that median overall', 'survival in the placebo arm will be around 9 months. 4,5 Based on a log-rank test, at', 'a', 'one-sided significance level of 0.0225 and a power of 90%, a total of 319 deaths among', 'subjects with DLL3', 'high are needed to detect an increase of median os to 13 months in', 'rovalpituzumab tesirine arm, corresponding to a hazard ratio of 0.69 (i.e., a reduction in', 'the hazard death of 31%). Assuming a 19-month accrual period and the last enrolled', 'subject followed for 12 months, at least 480 subjects with DLL3high are expected to be', 'randomized (240 subjects in each arm). A total of 740 subjects regardless of DLL3', 'expression level (including 480 subjects with DLL3high will enroll in the study, assuming', 'an approximate prevalence of 65% for subjects with DLL3high It is projected that an', 'observed hazard ratio of 0.795 or less, corresponding to a 2.3 months or greater', 'improvement in median OS, would result in a statistically significant improvement in the', 'final analysis of OS.', 'It is assumed, taking into account the expected patient population for the study, that', 'median progression-free survival for the placebo arm will be approximately 3 months. 4,5', 'Treatment with rovalpituzumab tesirine is hypothesized to increase median progression-', 'free survival to 4.5 months (i.e., a hazard ratio of 0.667). With approximately 407 PFS', 'events assessed by the CRAC for subjects with DLL3 high , the study provides a 90% power', 'to detect a hazard ratio of 0.667 in PFS at a one-sided significance level of 0.0025. It is', 'projected that an observed hazard ratio of 0.757 or less, corresponding to approximately', '197']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '1 month or greater improvement in median PFS, would result in a statistically significant', 'improvement in the PFS.', 'The primary analysis of PFS will take place when at least 407 CRAC assessed PFS events', 'and at least 239 deaths (an interim efficacy analysis of os with approximately 75% of', 'targeted 319 deaths) have occurred in subjects with DLL3high When both conditions', 'specified for the numbers of PFS and OS events are satisfied, the primary analysis of PFS', 'and the interim efficacy analysis of os will be performed at the same time. The final', 'analysis of OS is projected to be approximately 31 months from first subject enrolled', 'when approximately 319 deaths have occurred in subjects with DLL3 high', 'Has been changed to read:', 'There are two primary efficacy endpoints for this study: Progression-free survival (PFS)', 'based on the CRAC and overall survival (OS) in DLL3high ED SCLC patients. To', 'maintain the overall 1-sided type I error at a 2.5% for this study, the type I error will be', 'split, assigning 0.25% to progression-free survival and the remaining 2.25% to overall', 'survival. However, the OS endpoint will be tested at a one-sided 2.2499% significance', 'level as a one-sided alpha of 10-6 will be spent for the early look at the OS data for futility', 'analysis.', 'The sample size of the study is primarily determined by the analysis of OS. It is assumed,', 'taking into account the expected patient population for the study, that median overall', 'survival in the placebo and rovalpituzumab tesirine arm will be around 9 months and 13', 'months, respectively. The increase of median OS in rovalpituzumab tesirine arm', 'corresponds to a hazard ratio of 0.69, i.e., a reduction in the hazard of death by 31%.', 'With all these assumptions, a total of 319 deaths among subjects with DLL3 high are needed', 'to achieve a 90% power based on a log-rank test at a one-sided significance level of', '0.022499. Assuming a 19-month accrual period and the last enrolled subject followed for', '12 months, at least 480 subjects with DLL3 high are expected to be randomized', '(240 subjects in each arm). A total of 740 subjects regardless of DLL3 expression level', '(including 480 subjects with DLL3high) will enroll in the study, assuming an approximate', '198']\n\n###\n\n", "completion": "END"}